Report Scope This report aims to provide a comprehensive study of the global market for transdermal drug delivery technologies/systems. It provides a detailed description of the different types of transdermal drug delivery systems (passive and active) and the current and historical market revenues.
Transdermal drug delivery technologies/systems include passive transdermal drug delivery and active transdermal drug delivery. Passive transdermal drug delivery technologies/systems are segmented into matrix, reservoir and other transdermal drug delivery technologies/systems.
This report also offers a detailed study of therapeutic applications for transdermal drug delivery: pain, central nervous system (CNS) disorders, hormonal applications, smoking cessation, motion sickness, cardiovascular disorders and others. An in-depth analysis of the global market for transdermal drug delivery technologies/systems includes historical data and market projection of sales by technology/system type, therapeutic application, end-user and region.
For in-depth understanding of the market, profiles of market participants, key marketed products, competitive landscape, key competitors and respective market shares have been provided. This report also discusses driving and restraining factors of the global transdermal drug delivery technology/device market.
Report Includes - 60 tables
- An overview of the global markets for transdermal drug delivery (TDD) technologies/systems within the pharmaceutical industry
- Analyses of the global market trends, with data from 2020, estimates for 2021, and projections of compound annual growth rates (CAGRs) through 2026
- Market outlook and forecast trends of clinical application areas and end user segments of transdermal drug delivery technologies/systems
- Estimation of market size and revenue forecast for TDD market, and corresponding market share analysis by technology/system type, therapeutic application, end-user, and region
- Discussion of the key market dynamics (DROs), industry structure, regulatory approval, market deterrents, unmet needs and other factors driving opportunities in pharmaceutical research
- Review of patents, new developments and emerging technologies, clinical trials for many pipeline products, and potential markets for future developments
- Impact analysis of the Covid-19 pandemic on transdermal drug delivery systems market as against the overall pharmaceuticals industry
- Insight into recent industry activities, competitive landscape of the major players operating within the global market, and their corresponding company share analysis
- Profile descriptions of the leading drug delivery companies including AbbVie, Dr. Reddy’s Laboratories Ltd., Bayer, GlaxoSmithKline, Johnson & Johnson, Novartis AG, Teva Pharmaceutical, and Viatris
Summary Transdermal drug delivery systems (TDDSs: gels, patches, films, etc.) are placed on the skin and allow specific drug substances to penetrate into the bloodstream through the layers of the skin. TDDSs have many benefits compared to other methods of drug delivery (oral, injectable, etc.) TDDSs mitigate the hepatic first pass effect of drugs, offering safety and a better quality of life to the patient. TDDSs are used to treat a wide variety of conditions and diseases, including pain, CNS disorders, hormone imbalance, prevention of nausea and vomiting, cardiovascular diseases (CVD), overactive bladder and several others. Most TDDSs are available in the form of patches.
Transdermal drug delivery (TDD) is still a relatively niche segment, currently accounting for a small market share in the overall drug delivery market. However, given the many advantages (ease of use, better patient compliance, improved bioavailability and fewer adverse effects, etc.) over other drug delivery options (oral and injections) TDD has gained increasing attention over the last decade. TDDSs hold huge potential to address the needs of an increasing global elder population, especially in caregiver-intensive conditions and for patients with chronic conditions. Opportunity exists to translate drug needs into a dosage form that is more end-user (patient) and caregiver friendly. Regarding the patent cliff, TDD could make pharmaceutical companies more competitive. For example, a pharmaceutical company that focuses on life cycle management and TDD as a parallel path during development could be in a better position to extend the life of a drug and to strategically introduce a variety of formulations that drive patient preference.
The global TDD market is estimated to have been worth nearly $REDACTED in 2020.Between 2021 and 2026, the market is predicted to grow at a CAGR of REDACTED%, leading to a market value of $REDACTED in 2026.
The advent of innovative, new approaches and continuous technology development is the key factor driving growth in the market. The growing number of elder patients and the increasing demand for convenient drug delivery options with easy self-administration are also facilitating market growth.
TDD biologics (e.g., peptides, proteins, nucleic acids) and the use of new drug delivery devices such as microneedle systems for transdermal drug delivery, have high growth potential and are likely to have more activity in coming years. The opportunity areas in this market include TDD of large molecules underpinned by a large (multibillion) biologics market, wherein demand for advanced drug delivery systems is increasing.
Our reports have been used by over 10K customers, including:
Report Scope This report analyzes the market trends of microneedles with data from 2020, estimates for 2021, and projections of compound annual growth rates (CAGRs) through the forecast period of 2021 to 2026). Regulatory scenarios, drivers, restraints and opportunities will be covered, as well as market shares for leading...
539 pages •
By Roots Analysis Private Ltd.
• Jun 2021
Around 90% of the drug candidates in the current development pipeline and close to 40% of marketed pharmacological products, have been associated with concerns related to solubility and / or permeability. , In this context, considering modern regulatory standards, a large number of potential therapeutic leads...
175 pages •
By The Business Research Company
• Sep 2021
Major players in the autoinjectors market are AbbVie, Mylan, Eli Lilly and Company, Amgen, Becton Dickinson and Company, Johnson & Johnson, Teva Pharmaceutical, Merck, Pfizer, Bayer, Biogen, and AstraZeneca. The global autoinjectors market is expected to grow from $2.42 billion in 2020 to $2.94 billion in 2021 at a compound annual growth...
United States Connected Drug Delivery Devices Market, By Product Type (Connected Sensors v/s Integrated Connected Devices), By Technology (Bluetooth, Near Field Communication, Others), By Application (Asthma & COPD, Diabetes, Others), By End User (Healthcare Providers v/s Homecare), By Region, Competition Forecast & Opportunities,...
The global isosorbide market exhibited moderate growth during 2015-2020. Also known as D-Isosorbide dinitrate, isosorbide (C6H10O4) is a bio-product obtained from starch. The derivatives of isosorbide, namely isosorbide dinitrate and isosorbide mononitrate, find extensive applications across various end use industries...
693 pages •
By IQ4I Research & Consultancy Pvt. Ltd
• Jul 2021
Drug Delivery Systems (DDS) are the advanced formulations or technologies that modulate the release profile of therapeutic or prophylactic agents, their absorption, distribution and elimination characteristics to achieve the desired therapeutic effect and enhance the safety profile, patient convenience and compliance to medications...
Forecasts by Technology (Oral Drug Delivery Therapy, Injectable Drug Delivery, Topical Drug Delivery, Pulmonary Drug Delivery, Implantable Drug Delivery, Ocular Drug Delivery, Others), by Indication (Infectious Diseases, Cancer, Cardiovascular Diseases, Diabetes, Respiratory Diseases, Central Nervous System Disorders, Others), by Distribution...
Drug Delivery Technologies: Market Size From $1,451.50 billion in 2020, the global Drug Delivery Technologies market is projected to reach $3,203.09 billion by 2028. Based on our analysis the market is expected to grow at a CAGR of 10.4% from 2020 - 2028 timeframe. Some of the prominent trends that the market...
Microspheres: Market Size From $5.62 billion in 2020, the global Microspheres market is projected to reach $12.96 billion by 2028. Based on our analysis the market is expected to grow at a CAGR of 11.0% from 2020 - 2028 timeframe. Some of the prominent trends that the market is witnessing include, emerging economies...
175 pages •
By The Business Research Company
• May 2021
Major players in the implantable drug delivery devices market are Allergan Inc, Bayer HealthCare, Medtronic Inc., Nucletron, Boston Scientific Corporation, Abbott Laboratories, Bausch and Lomb Inc, Merck, Genetech Inc., and Psivida. The global implantable drug delivery devices market is expected to grow from $18.821 billion in 2020...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.